In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Inhale, 3-D Pharmaceuticals develop blood platelet drug

Executive Summary

3-Dimensional Pharmaceuticals (small-molecule drug discovery and development) has licensed Inhale's Shearwater subsidiary's PEGylation technology (acquired when Inhale bought the subsidiary last year) to further develop 3DP-3534, a PEGylated peptide in preclinical development to prevent and treat thrombocytopenia (low blood platelet count).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies